Volume 14 Issue 6, June 2017

Volume 14 Issue 6

Cover image supplied by Carolina Tropini, Sonnenburg Group, Stanford University, USA, who is funded by a James S. McDonnell fellowship. Fluorescent in situ hybridization of mouse colon colonized with gnotobiotic microbiota. Tissue was stained by DAPI and the mucus labelled with UEA-1 (Ulex europaeus agglutinin I), bacteria were labelled with fluorescent DNA probes.


Research Highlights

News and Views

  • News & Views |

    Cell culture infection models help to develop antiviral agents, but animal models are required to understand complex virus–host interactions and the development of immune therapies. Although identification of the HBV uptake receptor enabled establishing cell lines that replicate HBV from its natural transcription template, animal models supporting the full HBV life cycle are still lacking.

    • Ulrike Protzer
  • News & Views |

    Currently, no pharmacological therapies are approved for the treatment of NASH. A new study now identifies CASP8 and FADD-like apoptosis regulator (CFLAR) as a novel suppressor of NASH and its associated disorders in a process dependent on the activation of apoptosis signal-regulating kinase 1 (ASK1).

    • Susanne Schuster
    •  & Ariel E. Feldstein
  • News & Views |

    Patients with neuroendocrine tumours are increasingly treated with peptide receptor radionuclide therapy. However, tumour somatostatin receptor expression evaluation cannot accurately predict who will respond to therapy. Additional criteria to identify which patients are most likely to respond and those who will develop radiation-associated sequelae are critical requirements.

    • Mark Kidd
    •  & Irvin M. Modlin


  • Review Article |

    Gastrointestinal malignancies are among the most common human cancers. Genomic and transcriptomic analyses have identified recurring molecular subtypes that suggest important biological differences. Here, the authors review the common themes of gastrointestinal cancer subtypes, as well as how they could be implemented into clinical practice.

    • Maarten F. Bijlsma
    • , Anguraj Sadanandam
    • , Patrick Tan
    •  & Louis Vermeulen
  • Review Article |

    Lipid droplets (LDs) are dynamic organelles and many metabolic disorders results in abnormal lipid accumulation in the liver. This Review provides insights into LD biology and lipid homeostasis in the liver, as well as the role of LDs in liver diseases, including NAFLD, NASH and hepatitis C.

    • Nina L. Gluchowski
    • , Michel Becuwe
    • , Tobias C. Walther
    •  & Robert V. Farese Jr
  • Review Article |

    Evidence is growing that the gut microbiota can modulate the actions of chemotherapy. Here, the authors discuss the available data from human, animal and in vitro studies and describe the implications of pharmacomicrobiomics in cancer therapeutics.

    • James L. Alexander
    • , Ian D. Wilson
    • , Julian Teare
    • , Julian R. Marchesi
    • , Jeremy K. Nicholson
    •  & James M. Kinross